Program
trastuzumab rezetecan
Also written as “SHR-A1811”, “SHR-A1811 for Injection” and “SHR-A1811 Injection”.
Its studies are mostly in Breast Neoplasms · Carcinoma, Non-Small-Cell Lung · Stomach Neoplasms · Colorectal Neoplasms · Ovarian Neoplasms, led by Jiangsu HengRui Medicine.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jiangsu HengRui Medicine | 3632 open or running | phase 3since Jun 15, 2022 | Jun 18, 2020 | Dec 2026phase 2 · NCT06840002 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 19 studies since Jun 18, 2020.
- Sep 9, 2024Phase 2 study in Untreated Early-stage or Locally Advanced Breast CancerNCT06592625 · 60 planned · China
- Nov 25, 2024Phase 1 study in Advanced Breast CancerNCT06710990 · 17 enrolled · China
- Feb 10, 2025Phase 3 study in Ovarian NeoplasmsNCT06828354 · 300 planned · China
- Feb 17, 20252 phase 2 studiesNCT06840002, NCT06859775
- Jun 26, 2025Phase 2 study in RecurrenceNCT07051486 · 60 planned · China
- Jul 31, 2025Phase 2 study in Stomach NeoplasmsNCT07110571 · 200 planned · China
- Aug 1, 20252 phase 3 studiesNCT07111832, NCT07118527
- Aug 17, 2025Phase 2 study in Solid TumorNCT07140393 · 120 planned · China
- Sep 22, 2025Phase 3 study in Early-stage or Locally Advanced HER2-positive Breast CancerNCT07196774 · 740 enrolled · China
- Nov 27, 2025Phase 1 study in Solid TumorNCT07275242 · 107 planned · China
- Mar 19, 2026Phase 2 study in Unresectable Locally Recurrent Breast CancerNCT07497386 · 150 planned · China
- Jun 23, 20262 phase 3 studiesNCT07676162, NCT07679360
- Aug 28, 2026Phase 2 study in Advanced Colorectal Cancer Expressing HER2NCT07796763 · 48 planned · United States
- Oct 19, 2026Phase 3 study in Carcinoma, Non-Small-Cell LungNCT07896005 · 436 planned · China
Ahead
- Dec 2026Primary completion: phase 2 study in Ovarian NeoplasmsNCT06840002
- Dec 2026Primary completion: phase 2 study in Advanced Non-small Cell Lung CancerNCT05482568
- Dec 31, 2026Primary completion: phase 2 study in HER2 Expression / Amplification in Patients With Biliary Tract CancerNCT06413745
- Dec 31, 2026Primary completion: phase 3 study in HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and TaxaneNCT05424835
TargetBeta
“An antibody-drug conjugate (ADC) composed of trastuzumab, a humanized immunoglobulin G1-kappa (IgG1k) monoclonal antibody directed against the tumor-associated antigen (TAA) human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2) ”NCIt, by rule
Other programs on ERBB2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Trastuzumabrule | Hoffmann-La Roche | phase 4 | 85 |
| pertuzumabrule | Hoffmann-La Roche | phase 4 | 56 |
| trastuzumab deruxtecanrule | Daiichi Sankyo | phase 4 | 49 |
| tucatinibrule | Pfizer | phase 4 | 25 |
| disitamab vedotin | RemeGen | phase 3 | 36 |
| Lutetium-177 | Novartis | phase 3 | 24 |
| trastuzumab brengitecan | Sichuan Biokin Pharmaceutical | phase 3 | 21 |
| Gallium-68 | Philogen | phase 3 | 17 |
| zongertinibrule | Boehringer Ingelheim | phase 3 | 15 |
| Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102 | Sino Biopharmaceutical | phase 3 | 13 |
| sunvozertinibrule | Dizal Pharmaceuticals | phase 3 | 12 |
| anbenitamab | CSPC Pharmaceutical Group | phase 3 | 12 |
Studies
All 36 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07896005Carcinoma, Non-Small-Cell Lung · China | 3 | Not yet recruiting | Feb 2031 | 436 |
| NCT07796763Advanced Colorectal Cancer Expressing HER2 · United States | 2 | Not yet recruiting | May 1, 2028 | 48 |
| NCT07679360Triple Negative Breast Neoplasms · China | 3 | Recruiting | Dec 2030 | 1,000 |
| NCT07676162Advanced Colorectal Cancer · China | 3 | Recruiting | Sep 2029 | 300 |
| NCT07497386Unresectable Locally Recurrent Breast Cancer · China | 2 | Recruiting | Jun 2028 | 150 |
| NCT07275242Solid Tumor · China | 1 | Recruiting | Jun 2027 | 107 |
| NCT07196774Early-stage or Locally Advanced HER2-positive Breast Cancer · China | 3 | Active, not recruiting | Dec 2027 | 740 |
| NCT07140393Solid Tumor · China | 2 | Recruiting | Oct 2027 | 120 |
| NCT07118527Patients With Unresectable Locally Advanced or Metastatic Untreated Gastric or Gastroesophageal Junction Adenocarcinoma · China | 3 | Recruiting | Oct 2030 | 600 |
| NCT07111832Triple Negative Breast Neoplasms · China | 3 | Recruiting | Mar 2028 | 400 |
| NCT07110571Stomach Neoplasms · China | 2 | Recruiting | Aug 2026 | 200 |
| NCT07051486Recurrence · China | 2 | Recruiting | Feb 2026 | 60 |
| NCT06859775Recurrence · China | 2 | Recruiting | Oct 2026 | 100 |
| NCT06840002Ovarian Neoplasms · China | 2 | Recruiting | Dec 2026 | 150 |
| NCT06828354Ovarian Neoplasms · China | 3 | Recruiting | May 2027 | 300 |
| NCT06710990Advanced Breast Cancer · China | 1 | Completed | Oct 15, 2025 | 17 |
| NCT06592625Untreated Early-stage or Locally Advanced Breast Cancer · China | 2 | Not yet recruiting | Feb 28, 2026 | 60 |
| NCT06430437Non-Small Cell Lung Cancer With HER2- Mutations · China | 3 | Recruiting | Feb 2026 | 300 |
| NCT06413745HER2 Expression / Amplification in Patients With Biliary Tract Cancer · China | 2 | Active, not recruiting | Dec 31, 2026 | 59 |
| NCT06199973Advanced Colorectal Cancer · China | 3 | Active, not recruiting | Apr 2026 | 130 |
| NCT06222879Breast Neoplasms · China | 2 | Recruiting | Oct 31, 2026 | 350 |
| NCT06126640HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy · China | 3 | Active, not recruiting | Apr 2030 | 1,615 |
| NCT06123494HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma · China | 3 | Recruiting | Jun 30, 2027 | 360 |
| NCT06057610Breast Neoplasms · China | 3 | Active, not recruiting | Jul 15, 2026 | 868 |
| NCT05896020Gynaecological Malignancies · China | 2 | Recruiting | Jun 15, 2026 | 225 |
| NCT05845138Breast Neoplasms · China | 2 | Recruiting | Dec 31, 2024 | 116 |
| NCT05814354Breast Neoplasms · China | 3 | Active, not recruiting | Mar 20, 2026 | 551 |
| NCT05792410Breast Neoplasms | 2 | Not yet recruiting | Feb 27, 2024 | 300 |
| NCT05671822HER2 Expression Gastric Cancer/Gastroesophageal Junction Adenocarcinoma · China | 2 | Recruiting | Dec 2027 | 258 |
| NCT05482568Advanced Non-small Cell Lung Cancer · China | 2 | Recruiting | Dec 2026 | 324 |
| NCT05424835HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane · China | 3 | Active, not recruiting | Dec 31, 2026 | 381 |
| NCT05349409Advanced Solid Tumors · China | 2 | By invitation | Nov 30, 2024 | 212 |
| NCT05353361Breast Neoplasms · China | 2 | UNKNOWN | Dec 31, 2025 | 402 |
| NCT04818333Advanced Non-small Cell Lung Cancer · China | 2 | Active, not recruiting | Jun 2025 | 157 |
| NCT04513223Stomach Neoplasms · China | 1 | Completed | Mar 28, 2025 | 101 |
| NCT04446260Advanced Solid Tumors · United States, Australia, China and more | 1 | Completed | Jun 4, 2025 | 396 |
How it is read
Names in the registry
- “SHR-A1811”, 17 entries
- “SHR-A1811 for Injection”, 4 entries
- “SHR-A1811 Injection”, 3 entries
- “Trastuzumab Rezetecan for Injection”, 2 entries
- “SHR-A1811 and capecitabine”, 2 entries
Conditions, from the studies’ own filings
- Breast Neoplasms, 12 studies
- Carcinoma, Non-Small-Cell Lung, 4 studies
- Stomach Neoplasms, 4 studies
- Colorectal Neoplasms, 3 studies
- Ovarian Neoplasms, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.